Survival estimates for patients with Machado-Joseph disease (SCA3)
- PMID: 17894834
- DOI: 10.1111/j.1399-0004.2007.00910.x
Survival estimates for patients with Machado-Joseph disease (SCA3)
Abstract
Machado-Joseph disease (MJD), one of the most prevalent autosomal dominant cerebellar ataxias, is a neurodegenerative disease that starts during adulthood, with patients showing difficulties in gait, later becoming bedridden, and ultimately presenting premature death. There is, however, scarce data quantifying disease impact on patient survival. We investigated the overall survival of a large series of MJD patients and compared it with the survival of their asymptomatic relatives. A total of 412 affected and 413 unaffected individuals were ascertained from a consecutive sample of 82 families with a molecular diagnosis of MJD. Estimated mean survival time was 63.96 years [95% confidence interval (CI), 62.09-65.83] for the affected group and 78.61 years (95% CI, 74.75-82.47) for the unaffected group (p < 0.001). For a subset of 366 patients, mean age at onset was 36.37 years (95% CI, 35.21-37.53) and survival after disease onset was estimated as 21.18 years. Early onset and large CAG length predicted shorter overall survival times. This study presents quantitative data on the impact of MJD on overall survival, a phenomenon that is related to CAG length, age at onset, and year of birth.
Similar articles
-
Natural selection at the MJD locus: phenotypic diversity, survival and fertility among Machado-Joseph Disease patients from the Azores.J Biosoc Sci. 2001 Jul;33(3):361-73. doi: 10.1017/s0021932001003613. J Biosoc Sci. 2001. PMID: 11446399
-
Six cases of SCA3/MJD patients that mimic hereditary spastic paraplegia in clinic.J Neurol Sci. 2009 Oct 15;285(1-2):121-4. doi: 10.1016/j.jns.2009.06.027. Epub 2009 Jul 15. J Neurol Sci. 2009. PMID: 19608203
-
[Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Dec;25(6):660-2. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008. PMID: 19065526 Review. Chinese.
-
Does DNA methylation in the promoter region of the ATXN3 gene modify age at onset in MJD (SCA3) patients?Clin Genet. 2011 Jan;79(1):100-2. doi: 10.1111/j.1399-0004.2010.01508.x. Clin Genet. 2011. PMID: 21143471 No abstract available.
-
Machado-Joseph disease/spinocerebellar ataxia type 3.Handb Clin Neurol. 2012;103:437-49. doi: 10.1016/B978-0-444-51892-7.00027-9. Handb Clin Neurol. 2012. PMID: 21827905 Free PMC article. Review.
Cited by
-
Nerve growth factor for the treatment of spinocerebellar ataxia type 3: an open-label study.Chin Med J (Engl). 2015 Feb 5;128(3):291-4. doi: 10.4103/0366-6999.150087. Chin Med J (Engl). 2015. PMID: 25635421 Free PMC article.
-
Establish a Nomogram to Predict Falls in Spinocerebellar Ataxia Type 3.Front Neurol. 2021 Jan 27;11:602003. doi: 10.3389/fneur.2020.602003. eCollection 2020. Front Neurol. 2021. PMID: 33584500 Free PMC article.
-
Clinical Scales Predict Significant Videofluoroscopic Dysphagia in Machado Joseph Disease Patients.Mov Disord Clin Pract. 2015 May 9;2(3):260-266. doi: 10.1002/mdc3.12173. eCollection 2015 Sep. Mov Disord Clin Pract. 2015. PMID: 30363545 Free PMC article.
-
Preclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3.Biomedicines. 2021 Nov 24;9(12):1754. doi: 10.3390/biomedicines9121754. Biomedicines. 2021. PMID: 34944570 Free PMC article.
-
Flow cytometry allows rapid detection of protein aggregates in cellular and zebrafish models of spinocerebellar ataxia 3.Dis Model Mech. 2021 Oct 1;14(10):dmm049023. doi: 10.1242/dmm.049023. Epub 2021 Oct 11. Dis Model Mech. 2021. PMID: 34473252 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical